Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Roche Holding AG agreed to buy Telavant Holdings for $7.1 billion. The Swiss healthcare firm that operates pharmaceuticals and diagnostics businesses worldwide announced on Monday, Oct. 23, that it will acquire the developer of a new treatment for inflammatory bowel diseases that Roivant Sciences and Pfizer Inc. own with a minority stake.
According to Reuters, Roche Holding will have the right to develop, produce, and commercially market Roivant Sciences and Pfizer's experimental antibody called the RVT-3101 under the terms. Roche is aiming to release this drug in the United States and Japan.
RVT-3101 in Phase 3 Trial
Roche reportedly said the RVT-3101 is a "promising" new therapy currently being developed to help patients suffering from inflammatory bowel disease, ulcerative colitis, and Crohn's disease. This bowel disease is part of a chronic gastrointestinal disorder group that affects about eight million people worldwide.
It was added that 80% of the patients are not experiencing lasting remission. Roche believes that the new RVT-3101 or TL1A antibody has a big potential to help treat other diseases. The pharma company said the drug is already close to phase 3 of the trial.
"Promising" New Treatment
"We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," Roche Group's chief executive officer, Thomas Schinecker, said in a press release. "We are excited to add this promising new therapy in development to our portfolio and to make it available to patients as quickly as possible."
Roche's chief medical officer, who also serves as the company's head of global product development, further said, "The recent Phase 2b for RVT-3101 delivered the first long-term, robust dataset demonstrating improved clinical remission in the maintenance treatment phase and with this promising data, we believe that RVT-3101 has the potential to be the first therapy that offers both high efficacy and safety for people with inflammatory bowel disease and the convenience of an at-home, subcutaneous administration."
Photo by: Roche Media Library
